By Wang Fangqing
Chinese biotechs will seek more cross-border licensing deals in the coming years, especially for early-stage assets, said speakers at the annual China Healthcare Investment Conference (CHIC) held in late March in Shanghai.
“In-licensing deals are very challenging for Chinese biotech companies because they require a large amount of capital. That’s why we focus on early state assets. But it will require you have a strong R&D team,” said Frank Zhang, chief executive of the Nanjing-based contract research organization (CRO) GenScript, which owns the biotech firm Legend Biotech.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze